<DOC>
	<DOCNO>NCT01900652</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy study drug know LY2875358 , administer alone combination second drug name Erlotinib , participant affect defined type lung cancer ( MET biomarker diagnostic positive Non-Small-Cell Lung Cancer ) experience disease progression recent treatment Erlotinib .</brief_summary>
	<brief_title>A Study LY2875358 Non Small Cell Lung Cancer ( NSCLC ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Diagnosis metastatic Stage IV NSCLC At least 1 measurable extracentral nervous system ( CNS ) lesion Documented radiographic progression continuous treatment erlotinib monotherapy Objective clinical benefit erlotinib treatment define either document partial complete response stable disease ≥6 month , recent erlotinib treatment initiate base document epidermal growth factor receptor mutation ( EGFRmt ) status , least 12 week stable disease Determined MET diagnostic positive ( + ) Availability tumor sample posterlotinib progression Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Have adequate organ function Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device Have previously treat LY2875358 METtargeting experimental therapeutic Have serious concomitant systemic disorder significant cardiac disease Have interstitial pneumonia interstitial fibrosis lung pleural effusion , pericardial fluid ascites , require drainage every week frequently Have history another malignancy except basal squamous cell skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 3 year prior study Have major surgery le 2 week prior initiation study treatment therapy Pregnant lactate woman Have symptomatic CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>